Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research

Dallas, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, today announced significant progress in its ongoing H1N1 efficacy study conducted by Vipragen Biosciences ("Vipragen"), an AAALAC-accredited preclinical CRO in Mysuru, India, on its patented respiratory illness prevention technology in collaboration ...